

Congress of the United States

House of Representatives

COMMITTEE ON OVERSIGHT AND REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5051
MINORITY (202) 225-5074

<http://oversight.house.gov>

MEMORANDUM

March 4, 2019

To: Committee Members

Fr: Majority Staff

Re: Hearing on “The Trump Administration’s Response to the Drug Crisis”

On Thursday, March 7, 2019, at 10:00 a.m., in room 2154 of the Rayburn House Office Building, the Committee will hear testimony from the Director of the Office of National Drug Control Policy (ONDCP), which is charged with leading the Trump Administration’s national drug control efforts, including its response to the opioid crisis.

I. BACKGROUND

ONDCP was established within the Executive Office of the President by the Anti-Drug Abuse Act of 1988.¹ ONDCP is required to:

- (1) lead the national drug control effort, including coordinating with the National Drug Control Program Agencies;
- (2) coordinate and oversee the implementation of the national drug control policy, including the National Drug Control Strategy;
- (3) assess and certify the adequacy of National Drug Control Programs and the budget for those programs;
- (4) evaluate the effectiveness of national drug control policy efforts, including the National Drug Control Program Agencies’ program, by developing and applying specific goals and performance measurements and monitoring the agencies’ program-level spending;
- (5) identify and respond to emerging drug threats related to illicit drug use;

¹ Pub. L. 100-690.

- (6) administer the Drug-Free Communities Program, the High-Intensity Drug Trafficking Areas Program, and other grant programs directly authorized to be administered by the Office in furtherance of the National Drug Control Strategy; and
- (7) facilitate broad-scale information sharing and data standardization among Federal, State, and local entities to support the national drug control efforts.”²

ONDCP was reauthorized last year by the SUPPORT for Patients and Communities Act.³ Many of the provisions included in the reauthorization derived from H.R. 5925, the Coordinated Response Through Interagency Strategy and Information Sharing Act (CRISIS Act), bipartisan legislation developed by then-Chairman Trey Gowdy and then-Ranking Member Elijah Cummings, as well as Reps. Mark Meadows and Gerry Connolly.

II. HEARING PURPOSE

The hearing will examine ONDCP’s coordination of national drug control efforts, including the Administration’s response to the opioid crisis. The hearing will also examine ONDCP’s implementation of the provisions of the SUPPORT for Patients and Communities Act that reauthorized the agency.

III. WITNESSES

Panel One

The Honorable James W. Carroll, Jr.
Director
Office of National Drug Control Policy

Panel Two

Triana McNeil
Acting Director, Strategic Issues
Government Accountability Office

Staff contacts: Lucinda Lessley, Courtney French, and Miles Lichtman at (202) 225-5051.

² 21 U.S.C. §1702.

³ Pub. L. 115-271.